Evaluation of σ-1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET

J Nucl Med. 2014 Jan;55(1):147-53. doi: 10.2967/jnumed.113.120261. Epub 2013 Dec 12.

Abstract

The noninvasive imaging of σ-1 receptors (S1Rs) could provide insight into their role in different diseases and lead to novel diagnostic/treatment strategies. The main objective of this study was to assess the S1R radiotracer (18)F-FTC-146 in rats. Preliminary squirrel monkey imaging and human serum/liver microsome studies were performed to gain information about the potential of (18)F-FTC-146 for eventual clinical translation.

Methods: The distribution and stability of (18)F-FTC-146 in rats were assessed via PET/CT, autoradiography, γ counting, and high-performance liquid chromatography (HPLC). Preliminary PET/MRI of squirrel monkey brain was conducted along with HPLC assessment of (18)F-FTC-146 stability in monkey plasma and human serum.

Results: Biodistribution studies showed that (18)F-FTC-146 accumulated in S1R-rich rat organs, including the lungs, pancreas, spleen, and brain. Pretreatment with known S1R compounds, haloperidol, or BD1047, before radioligand administration, significantly attenuated (18)F-FTC-146 accumulation in all rat brain regions by approximately 85% (P < 0.001), suggesting radiotracer specificity for S1Rs. Similarly, PET/CT and autoradiography results demonstrated accumulation of (18)F-FTC-146 in rat brain regions known to contain S1Rs and that this uptake could be blocked by BD1047 pretreatment. Ex vivo analysis of (18)F-FTC-146 in the brain showed that only intact radiotracer was present at 15, 30, and 60 min, whereas rapid metabolism of residual (18)F-FTC-146 was observed in rat plasma. Preliminary monkey PET/MRI studies demonstrated specific accumulation of (18)F-FTC-146 in the brain (mainly in cortical structures, cerebellum, and vermis) that could be attenuated by pretreatment with haloperidol. HPLC of monkey plasma suggested radioligand metabolism, whereas (18)F-FTC-146 appeared to be stable in human serum. Finally, liver microsome studies revealed that (18)F-FTC-146 has a longer half-life in human microsomes, compared with rodents.

Conclusion: Together, these results indicate that (18)F-FTC-146 is a promising tool for visualizing S1Rs in preclinical studies and that it has potential for mapping these sites in the human brain.

Keywords: 18F; PET; σ-1 receptor.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Azepines / chemistry*
  • Benzothiazoles / chemistry*
  • Brain / pathology
  • Chromatography, High Pressure Liquid
  • Humans
  • Ligands
  • Magnetic Resonance Imaging
  • Male
  • Mice
  • Microsomes, Liver / metabolism
  • Positron-Emission Tomography*
  • Protein Binding
  • Radiopharmaceuticals / chemistry*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, sigma / chemistry*
  • Saimiri
  • Sigma-1 Receptor
  • Tissue Distribution
  • Tomography, X-Ray Computed

Substances

  • 6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo(d)thiazol-2(3H)-one
  • Azepines
  • Benzothiazoles
  • Ligands
  • Radiopharmaceuticals
  • Receptors, sigma